At the ESMO Immuno-Oncology Congress 2022, Compugen Inc. shared phase I data for COM-701 in dual and triple combination with Bristol Meyers Squibb Co.’s Opdivo (nivolumab) and with or without BMS-986207.
At the ESMO Immuno-Oncology Congress 2022, Compugen Inc. shared phase I data for COM-701 in dual and triple combination with Bristol Meyers Squibb Co.’s Opdivo (nivolumab) and with or without BMS-986207. Compugen’s candidate demonstrated preliminary durable antitumor activity and immune activation in patients with platinum resistant ovarian cancer with a favorable safety and toxicity profile.
New and updated clinical data presented by biopharma firms at the ESMO Immuno-Oncology Congress 2022, including: Immunocore, Jounce, NGM, Promontory, Rapt.
Top-line phase III results showing Hutchmed Ltd.’s targeted therapy fruquintinib reduced the risks of death and disease progression by 34% and 68%, respectively, for patients with metastatic colorectal cancer could “lay a solid foundation for Hutchmed to initiate discussions with regulatory authorities worldwide,” a spokesperson of Hutchmed, told BioWorld.
New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2022, including: Alphamab, Beyondspring, Triumvira.
Top-line phase III results showing Hutchmed Ltd.’s targeted therapy fruquintinib reduced the risks of death and disease progression by 34% and 68%, respectively, for patients with metastatic colorectal cancer could “lay a solid foundation for Hutchmed to initiate discussions with regulatory authorities worldwide,” a spokesperson of Hutchmed, told BioWorld.
New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2022, including: Akeso, PDC*Line, Starpharma, Transcenta, Zymeworks.
Despite wide availability and coverage for colonoscopy, many patients diagnosed with colorectal cancer (CRC) have never undergone the recommended screening procedure for the malignancy and its precursors. As a result, the cancer has already spread in the majority of cases at the time of diagnosis. CRC remains the third most common cancer diagnosed in the U.S. and the second leading cause of cancer death for both men and women.
Genexine Co. Ltd.’s DNA vaccine, GX-188E, showed potential in extending overall survival in patients with advanced cervical cancer in a phase II study when given in combination with Merck & Co. Inc.’s anti-PD-1 therapy, Keytruda (pembrolizumab). The Seoul, Korea-based company analyzed 60 patients with human papillomavirus (HPV)-16 or HPV-18-positive advanced cervical cancer who had progressed after standard-of-care therapy.
RSS
